Risk Management# Stock
n*8
1 楼
Have made half of the mistakes.
http://prudentvalueinvestor.blogspot.com/2015/01/risk-managemen
IPO of new biotech company without approved product and little money on
balance sheet, but with optimistic valuation.
Any overvalued IPO of the company that is loss making and without any
clear path to profitability in the near future, even if the company offers a
product that looks promising.
Bets on turnaround of oversold company in declining industry (e.g. coal
industry now days) with negative cash flows and significant amount of debt.
Small caps with very low market liquidity that can look even cheap on
the surface.
Small caps which business and therefore valuation depends on litigation
outcome.
Bets on company in restructuring process, that outcome cannot be easily
predicted.
Very popular highly priced momentum stocks, that usually very volatile
and growths on implausible expectations and/or rumors.
http://prudentvalueinvestor.blogspot.com/2015/01/risk-managemen
IPO of new biotech company without approved product and little money on
balance sheet, but with optimistic valuation.
Any overvalued IPO of the company that is loss making and without any
clear path to profitability in the near future, even if the company offers a
product that looks promising.
Bets on turnaround of oversold company in declining industry (e.g. coal
industry now days) with negative cash flows and significant amount of debt.
Small caps with very low market liquidity that can look even cheap on
the surface.
Small caps which business and therefore valuation depends on litigation
outcome.
Bets on company in restructuring process, that outcome cannot be easily
predicted.
Very popular highly priced momentum stocks, that usually very volatile
and growths on implausible expectations and/or rumors.